| epirubicin / Generic mfg. |
2010-023484-17: Sarcomas de partes blandas localizados de alto riesgo de extremidades y pared de tronco en adultos: un enfoque integrador que incluye tratamiento con medicamentos antitumorales estándar comparado con tratamientos específicos para las diferentes variedades histológicas como primer tratamiento. |
|
|
| Ongoing | 3 | 250 | Europe | epirrubicina, ifosfamida, Gemcitabina, Docetaxel, Etoposido, FARMIBLASTINA, Dacarbazina, epirubicin, ifosfamide, gemcitabine, docetaksel, etoposide, dacarbazine, epirubicin, ifosfamide, gemcitabine, docetaksel, etoposide, dacarbazine | ITALIAN SARCOMA GROUP, Grupo Español de Investigación en Sarcomas, Italian Sarcoma Group, , Grupo Español de Investigación en Sarcomas, NHS (diagnostic and therapeutic procedures), Eurosarc, funded by project/grant FP7 | High risk localized soft tissue sarcomas typical of the adult | | | | |
2019-003543-30: A study to test the effect of chemotherapy before surgery compared to surgery alone in patients with high risk retroperitoneal sarcoma |
|
|
| Ongoing | 3 | 250 | Europe | Doxorubicin, Epirubicin, Dacarbazin, Ifosfamide, [Doxorubicin], [Epirubicin], [Dacarbazin], [Ifosfamide], Solution for infusion, Solution for injection/infusion, Powder for solution for injection/infusion | European Organisation for Research and Treatment of Cancer, EORTC AISBL/IVZW, European Organisation for the Research and Treatment of Cancer, Anticancer fund | Primary high risk leiomyosarcoma or Liposarcoma of retroperitoneal space or infra-peritoneal spaces of pelvis, Retroperitoneal sarcoma: a sarcoma developed in the back of the belly, next to the kidneys, in a relatively “hidden” location known as the retroperitoneum., Diseases [C] - Cancer [C04] | | | | |
NCT05121350: A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma |
|
|
| Recruiting | 3 | 256 | RoW | Anlotinib hydrochloride capsule, Epirubicin, Arotinib hydrochloride capsule placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Soft Tissue Sarcoma | 06/24 | 06/24 | | |
ISG-STS-1001, NCT01710176: Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy |
|
|
| Active, not recruiting | 3 | 550 | Europe | epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3), gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8), trabectedin 1.3 mg/m2, high-dose ifosfamide 14 g/m2, given in in 14 days, etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3), gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1) | Italian Sarcoma Group, French Sarcoma Group, Grupo Espanol de Investigacion en Sarcomas | Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults | 06/24 | 06/24 | | |
| Recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | Surgery, Preoperative chemotherapy, neoadjuvant chemotherapy | European Organisation for Research and Treatment of Cancer - EORTC, Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group, Anticancer Fund, Belgium, Australia and New Zealand Sarcoma Association, Japan Clinical Oncology Group | Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma | 04/27 | 04/28 | | |
ChiCTR1900024928: Efficacy and safety of Anlotinib plus Epirubicin civ followed by Anlotinib sequential therapy in the first-line chemotherapy for advanced soft tissue sarcoma (STS): A single-arm phase 2 clinical trial |
|
|
| Not yet recruiting | 2 | 30 | | An+EPI→An | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Self-funding | Sarcoma | | | | |
NCT05204524: Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma |
|
|
| Recruiting | 2 | 28 | RoW | Temozolomide for injection combined with epirubicin | Chinese Academy of Medical Sciences | Leiomyosarcoma | 08/22 | 08/23 | | |
ChiCTR2100048014: A multi-center, single-arm clinical trial of penpulimab (AK105) combined with anlotinib hydrochloride and epirubicin in the first-line treatment of soft tissue sarcoma |
|
|
| Not yet recruiting | 1/2 | 78 | | Penpulimab + Anlotinib Hydrochloride + Epirubicin（dose escalation） ;Penpulimab + Anlotinib Hydrochloride + Epirubicin | Zhongshan Hospital of Fudan University; Zhongshan Hospital of Fudan University, Partly self-funded，partly provied by CTTQ. | Sarcoma | | | | |
| Recruiting | 1/2 | 270 | Europe | Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Sutent, Nivolumab 100 MG/10 ML [Opdivo], Opdivo, Epirubicin, Ifosfamide, Doxorubicin, Dacarbazine, Cisplatin, Methotrexate | Grupo Espanol de Investigacion en Sarcomas | Soft Tissue Sarcoma, Bone Sarcoma | 06/25 | 06/25 | | |
NCT06038552: The Long-term Efficacy of Imatinib With Hepatic Resection or Other Local Treatment for GIST Liver Metastases |
|
|
| Completed | N/A | 238 | RoW | imatinib (IM), Gleevec, hepatic resection (HR), radiofrequency ablation (RFA), transarterial chemoembolization (TACE) | First Affiliated Hospital, Sun Yat-Sen University | GIST, Malignant, Liver Metastases | 12/22 | 05/23 | | |
ChiCTR2000028961: Combination of high-throughput sequencing and primary cell culture as an exploratory study of individualized treatment of malignant tumors: phase 2 clinical trial of sintilimab for retroperitoneal dedifferentiation of liposarcoma |
|
|
| Not yet recruiting | N/A | 30 | | Neoadjuvant sintilimab monotherapy ;Neoadjuvant sintilimab combined with epirubicin and/or ifosfamide | Department of Urology, Shanghai Changhai Hospital, the Second Military Medical University, Shanghai, China; Second Military Medical University, Innovent Biologics, Inc. | retroperitoneal dedifferentiated liposarcoma | | | | |
